Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07472647 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

SYS6090 Combination Therapy in Advanced Lung Cancer

Name: SYS6090 Combination Therapy in Advanced Lung Cancer — clinical trial record (NCT07472647)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 1/2

SponsorShanghai JMT-Bio Inc.

Started2026-02-28

View on ClinicalTrials.gov ↗

Shanghai JMT-Bio Inc.

31 trials monitored

See all monitored trials

Lung Cancer

4,033 trials monitored

See 210 trials at risk

Non-Small Cell Lung Cancer (NSCLC)

2,914 trials monitored

See 156 trials at risk

Small Cell Lung Cancer

539 trials monitored

See 30 trials at risk

This is an open-label, multi-cohort, multicenter Phase Ib/II clinical study designed to evaluate the safety, tolerability, and efficacy of SYS6090 injection in combination with chemotherapy or chemotherapy and bevacizumab or SYS6010 (an EGFR ADC) in participants with advanced lung cancer.

Trial Details

NCT Number	NCT07472647
Lead Sponsor	Shanghai JMT-Bio Inc.
Conditions	Non-Small Cell Lung Cancer, Small Cell Lung Cancer
Enrollment	596 participants
Start Date	2026-02-28
Primary Completion	2029-02-28 (estimated)
Study Completion	2030-02-28 (estimated)
Updated on ClinicalTrials.gov	2026-03-16